Seattle Genetics opts for another ADC under Agensys alliance
This article was originally published in Scrip
Executive Summary
Investors appeared to welcome a decision by Seattle Genetics to exercise an option to co-develop another antibody-drug conjugate (ADC) with its strategic partner Agensys, driving up shares in the Bothell, Washington-based firm by 2.1% to $31.51 on 27 June, the day the deal was announced.